

REMARKS

In response to the restriction requirement mailed March 24, 2010, Applicants hereby elect Group II, drawn to a microarray device, corresponding to claims 2-9. See the Office Action at 2. Claims 11-19 are withdrawn, while claims 1 and 10 are canceled. Claim 2 has been amended to incorporate the subject matter of canceled claim 1. Claim 17 has been amended to depend from claim 2.

The Examiner has further required an election of species for Group II. Office Action at 5-6. Specifically, "applicant should further specify and elect a single combination of oligonucleotides selected from the list presented in claim 1." In this regard, Applicants elect the following combination of oligonucleotides selected from the list presented in claim 1: SEQ ID NOS 72-73, 76-81, 84-91 and 5-63. It is noted that this combination is presented in Fig. 18 and discussed in the Example. See the specification at 42-46. For clarity, each of the oligonucleotides belonging to the elected combination is listed below:

GAAGCCCAGCAATTGCGTGTTTC (SEQ ID NO: 72)
 GAAGCCCAGCAACTGCGTGTTTC (SEQ ID NO: 73)
 GGTGCTGCAGGGTGTTCGCCGG (SEQ ID NO: 76)
 GGTGCTGCAGGGCGTTTCGCCGG (SEQ ID NO: 77)
 CAAGATCGCCGCAGCGGTCAAC (SEQ ID NO: 78)
 CAAGATCGCCGCTGCGGTCAAC (SEQ ID NO: 79)
 TGCTGCTGGCGGCGGTGTGCTAT (SEQ ID NO: 80)
 TGCTGCTGGCAGCGGTGTGCTAT (SEQ ID NO: 81)
 CCTCGCCCTGTTCCCGCTCTGG (SEQ ID NO: 84)
 CTCGCCCTGTTCCCGCTCTGG (SEQ ID NO: 85)
 TCGAGCAACTGGCAGAGAAATCCG (SEQ ID NO: 86)
 CGAGCAACTGGCGGAGAAATCCG (SEQ ID NO: 87)
 GCGGAAACTTCCTGCACATGATGTT (SEQ ID NO: 88)
 GCGGAAACTTCCTCCACATGATGTT (SEQ ID NO: 89)

AGCTCAGCAGACTGCTGACGAGG (SEQ ID NO: 90)
AGCTCAGCAGACCGCTGACGAG (SEQ ID NO: 91)
AAGAGGACGGCCGCCGGGTGACGCC (SEQ ID NO: 5)
AAGAGGACGGCCGCCAGGTGACGCCG (SEQ ID NO: 6)
GACAAGATGCGCCTCGACGACC (SEQ ID NO: 7)
GACAAGATGCGTCTCGACGACCG (SEQ ID NO: 8)
AGCCGACCTACGCGCCGGGCAG (SEQ ID NO: 9)
CAGCCGACCTATGCGCCGGGCAG (SEQ ID NO: 10)
CCGTTCGAACGGCTCATGGAGCA (SEQ ID NO: 11)
GCCGTTTGAACGACTCATGGAGCA (SEQ ID NO: 12)
TGGAGCAGCAAGTGTTCCCGGC (SEQ ID NO: 13)
TGGAGCAGCAACTGTTCCCGGC (SEQ ID NO: 14)
GAACAAGACCGGTTCCACCAACGG (SEQ ID NO: 15)
AACAAGACCGGCTCCACCAACGG (SEQ ID NO: 16)
GCGACCTGGGCCTGGTGATCCT (SEQ ID NO: 17)
GCGACCTGGGACTGGTGATCC (SEQ ID NO: 18)T
GCCGACCAACTGAACTCCAACCTCG (SEQ ID NO: 19)
GTCGCTGAACGGCACCTACTTCA (SEQ ID NO: 20)
CAGCCTGCGGTCATGTCCTCGG (SEQ ID NO: 21)
CGCCAGTTTGAGAACGGAGTCACC (SEQ ID NO: 22)
GCGCGATCTTCTCCACTTCATCGG (SEQ ID NO: 23)
GCCTCCGCGATTGAACATCGTGAT (SEQ ID NO: 24)
GTAGCCGGAGTCGAGCGGAATCAT (SEQ ID NO: 25)
GTGAGCATGGAATCGGCAGTCGTT (SEQ ID NO: 26)
CGAGGAGTTTCGGACCCGCTTTGA (SEQ ID NO: 27)
AATAGGACCGGCAGAACGGGCATT (SEQ ID NO: 28)
GCGCCTTCTCCTCTTTGCAGATGT (SEQ ID NO: 29)
CAGTATGGTACGGACACGAAGCGC (SEQ ID NO: 30)
GCATCATTGCGCGTCACATCTGGT (SEQ ID NO: 31)
TCTGAACTGCGGCTATCACCTGGA (SEQ ID NO: 32)
AATTGATGGCTTCTCAGGCGCAGG (SEQ ID NO: 33)
AGTCATGGGACTGAATACGGCGACT (SEQ ID NO: 34)
TTCTCGGTGTCGAGGGATTCTCGG (SEQ ID NO: 35)
TGGTAGCTCTCGACGTAAGGCTG (SEQ ID NO: 36)


CCCGTTGCTCATAACCCGTTCTG (SEQ ID NO: 37)
AGGGCATTCTCAGGTGGACTCAGG (SEQ ID NO: 38)
ACCTGTGTCGCTGGAGGGTATGTT (SEQ ID NO: 39)
AGCGTCCCTGACCAACCTCATCAG (SEQ ID NO: 40)
CGCCAACAATTCGCCATTACAGCG (SEQ ID NO: 41)
TCCAACAGGCAGGAGTACAGGGTG (SEQ ID NO: 42)
CGCTGCACATACAGGTCCGTTCTC (SEQ ID NO: 43)
AGCCCAGCAATTGCGTGTTTCTCCG (SEQ ID NO: 44)
AGCCCAGCAACTGCGTGTTTCTCC (SEQ ID NO: 45)
GCTGCTGGCGGCGGTGTGC (SEQ ID NO: 46)
TGCTGCTGGCAGCGGTGTGCT (SEQ ID NO: 47)
CAGAAAGCTCAGCAGACTGCTGACGAG (SEQ ID NO: 48)
GAAAGCTCAGCAGACCGCTGACGAG (SEQ ID NO: 49)
ACGGCCGCCGGGTGACGCC (SEQ ID NO: 50)
ACGGCCGCCAGGTGACGCCG (SEQ ID NO: 51)
GCCGACCTACGCGCCGGGC (SEQ ID NO: 52)
AGCCGACCTATGCGCCGGGCA (SEQ ID NO: 53)
GTTCGAACGGCTCATGGAGCAGCA (SEQ ID NO: 54)
GTTCGAACGACTCATGGAGCAGCAAG (SEQ ID NO: 55)
CAGCCCAGTCAGGACGCGCA (SEQ ID NO: 56)
AGTGACGTGCGTTTCAGCAGTCCC (SEQ ID NO: 57)
GTGTCACGGCCCATGTCTAGCAGC (SEQ ID NO: 58)
CGAAGTCTGAGGTGTGGACCCGC (SEQ ID NO: 59)
CGCTGGAGGGTATGTTCCGCAAGG (SEQ ID NO: 60)
CGTACTCAGCTTCTCCACCCAGCG (SEQ ID NO: 61)
CCTGGACCTCTCCAAGGTTGCCT (SEQ ID NO: 62)
GCCATTCCGACGACCAACAAGGC (SEQ ID NO: 63)

With regard to Group III, claims 11-19 are directed to methods, and depend from claim 2, drawn to a product. As such, claims 11-19 will be eligible for rejoinder should the product claims be found allowable. See the Office Action at 8.

The Examiner is invited to contact the undersigned by telephone if it is felt that a telephone interview would advance the prosecution of the present application. Applicants respectfully ask that all claims be allowed.

Respectfully submitted,

Date 4-26-10

By 
Harold H. Fox
Registration No. 41,498

STEPTOE & JOHNSON, LLP
1330 Connecticut Avenue
Washington, DC 20036
Telephone: 202-429-3000
Facsimile: 202-429-3902

Should additional fees be necessary in connection with the filing of this paper, or if a petition for extension of time is required for timely acceptance of same, the Commissioner is hereby authorized to charge **Deposit Account No. 19-4293** for any such fees; and applicants hereby petition for any needed extension of time.